title: M₅ muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice.
abstract: Opiates, like other addictive drugs, elevate forebrain dopamine levels and are thought to do so mainly by inhibiting GABA neurons near the ventral tegmental area (VTA), in turn leading to a disinhibition of dopamine neurons. However, cholinergic inputs from the laterodorsal (LDT) and pedunculopontine (PPT) tegmental nucleus to the VTA and substantia nigra (SN) importantly contribute, as either LDT or PPT lesions strongly attenuate morphine-induced forebrain dopamine elevations. Pharmacological blockade of muscarinic acetylcholine receptors in the VTA or SN has similar effects. M₅ muscarinic receptors are the only muscarinic receptor subtype associated with VTA and SN dopamine neurons. Here we tested the contribution of M₅ muscarinic receptors to morphine-induced dopamine elevations by measuring nucleus accumbens dopamine efflux in response to intra-VTA morphine infusion using in vivo chronoamperometry. Intra-VTA morphine increased nucleus accumbens dopamine efflux in urethane-anesthetized wildtype mice starting at 10 min after infusion. These increases were absent in M₅ knockout mice and were similarly blocked by pre-treatment with VTA scopolamine in wildtype mice. Furthermore, in wildtype mice electrical stimulation of the PPT evoked an initial, short-lasting increase in striatal dopamine efflux, followed 5 min later by a second prolonged increase in dopamine efflux. In M₅ knockout mice, or following systemic pre-treatment with scopolamine in wildtype mice, the prolonged increase in striatal dopamine efflux was absent. The time course of increased accumbal dopamine efflux in wildtype mice following VTA morphine was consistent with both the prolonged M₅-mediated excitation of striatal dopamine efflux following PPT electrical stimulation and accumbal dopamine efflux following LDT electrical stimulation. Therefore, M₅ receptors appear critical for prolonged PPT excitation of dopamine efflux and for dopamine efflux induced by intra-VTA morphine.
authors.affiliation: Department of Psychology, University of Toronto, Toronto, Ontario, Canada. ssteidl@nida.nih.gov
authors.forename: Stephan
authors.initials: S
authors.lastname: Steidl
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Miller
authors.forename: Charles D
authors.initials: CD
authors.lastname: Blaha
authors.forename: John S
authors.initials: JS
authors.lastname: Yeomans
mesh_terms: D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D004558:Electric Stimulation; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009020:Morphine / Q000494:pharmacology*; D045042:Pedunculopontine Tegmental Nucleus / Q000378:metabolism*; D043642:Receptor, Muscarinic M5 / Q000502:physiology*; D017557:Ventral Tegmental Area / Q000378:metabolism*
chemical_list: D043642:Receptor, Muscarinic M5; D009020:Morphine; D004298:Dopamine
references.citation: Eur J Pharmacol. 2007 May 7;562(1-2):92-102
references.pmid: 17336285
references.citation: Neuroscience. 1984 Mar;11(3):617-25
references.pmid: 6717805
references.citation: Proc Natl Acad Sci U S A. 1990 Sep;87(18):7050-4
references.pmid: 2402490
references.citation: J Neurosci. 2002 Jan 1;22(1):RC190
references.pmid: 11756520
references.citation: Neuroscience. 2010 Dec 15;171(3):812-29
references.pmid: 20884335
references.citation: Brain Res. 1988 May 31;450(1-2):86-93
references.pmid: 3261193
references.citation: Eur J Neurosci. 2005 Apr;21(7):1837-46
references.pmid: 15869479
references.citation: Neuroscience. 1997 Aug;79(4):1089-109
references.pmid: 9219969
references.citation: Neuron. 2002 Oct 10;36(2):229-40
references.pmid: 12383779
references.citation: Mol Pharmacol. 1994 Dec;46(6):1028-35
references.pmid: 7808421
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50
references.pmid: 1347943
references.citation: Neuropsychopharmacology. 2011 Feb;36(3):589-602
references.pmid: 21048703
references.citation: Behav Pharmacol. 1996 Nov;7(7):675-708
references.pmid: 11224465
references.citation: J Neurosci. 1995 Sep;15(9):5859-69
references.pmid: 7666171
references.citation: Pharmacol Biochem Behav. 2002 May;72(1-2):117-23
references.pmid: 11900778
references.citation: Neuroscience. 2002;111(2):351-62
references.pmid: 11983320
references.citation: J Neurosci. 1998 Jul 1;18(13):5035-44
references.pmid: 9634569
references.citation: J Neurosci. 2006 Jan 11;26(2):398-405
references.pmid: 16407535
references.citation: J Neurosci. 1993 Mar;13(3):1035-44
references.pmid: 8441002
references.citation: Pharmacol Biochem Behav. 1991 Jun;39(2):469-72
references.pmid: 1946587
references.citation: J Neurosci. 1996 Jan 15;16(2):714-22
references.pmid: 8551354
references.citation: J Pharmacol Exp Ther. 2009 Jan;328(1):263-75
references.pmid: 18849356
references.citation: Neuroscience. 2002;114(4):817-23
references.pmid: 12379238
references.citation: J Comp Neurol. 2009 Apr 20;513(6):566-96
references.pmid: 19235216
references.citation: Brain Res. 1983 Oct 24;277(1):119-27
references.pmid: 6315137
references.citation: Life Sci. 2001 Apr 27;68(22-23):2449-56
references.pmid: 11392612
references.citation: Behav Brain Res. 1994 Dec 15;65(2):205-11
references.pmid: 7718153
references.citation: J Neurosci. 1990 Aug;10(8):2541-59
references.pmid: 2388079
references.citation: Eur J Neurosci. 2000 Oct;12(10):3596-604
references.pmid: 11029630
references.citation: Eur J Neurosci. 2003 Feb;17(4):751-62
references.pmid: 12603265
references.citation: Neurosci Lett. 1990 Jul 3;114(2):154-9
references.pmid: 2395528
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11452-7
references.pmid: 12154229
references.citation: Nat Neurosci. 2004 Feb;7(2):160-9
references.pmid: 14730310
references.citation: Neuroscience. 2005;136(2):531-8
references.pmid: 16216430
references.citation: J Neurosci. 1992 Feb;12(2):483-8
references.pmid: 1346804
references.citation: Behav Neurosci. 1992 Oct;106(5):798-807
references.pmid: 1359898